人福医药
(600079)
| 流通市值：314.81亿 | | | 总市值：332.97亿 |
| 流通股本：15.43亿 | | | 总股本：16.32亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 3,553,564,997.79 | 3,915,043,500.34 | 3,843,946,765.2 | 3,554,890,765.94 |
| 衍生金融资产 | 4,574,294.24 | 5,429,884.46 | 6,229,076.03 | 8,439,674.58 |
| 应收票据及应收账款 | 10,061,615,241.99 | 9,271,189,967.02 | 9,820,834,269.61 | 9,462,627,285.88 |
| 其中：应收票据 | 74,193,209.44 | 72,972,041.62 | 80,440,880.75 | 89,343,142.04 |
| 应收账款 | 9,987,422,032.55 | 9,198,217,925.4 | 9,740,393,388.86 | 9,373,284,143.84 |
| 应收款项融资 | 1,143,596,649.9 | 1,129,357,185.78 | 793,523,974.52 | 937,740,567.26 |
| 预付款项 | 455,517,353.63 | 407,818,094.24 | 545,483,503.99 | 618,394,315.75 |
| 其他应收款合计 | 419,192,534.63 | 283,124,705.48 | 405,467,774.39 | 454,220,645.74 |
| 存货 | 3,483,780,612.13 | 3,566,397,534.27 | 3,922,531,611.8 | 3,878,475,974.29 |
| 其他流动资产 | 256,080,857.92 | 245,410,547.55 | 230,244,291.25 | 229,839,540.17 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 20,412,196,364.83 | 19,858,374,856.88 | 20,487,118,563.49 | 20,071,470,540.7 |
| 非流动资产: | | | | |
| 长期应收款 | 336,784,606.31 | 336,784,606.31 | 381,768,052.39 | 400,925,552.39 |
| 长期股权投资 | 1,096,287,125.13 | 1,074,115,819.69 | 1,107,418,683.91 | 1,100,500,484.67 |
| 其他权益工具投资 | 707,540,143.98 | 741,914,805.6 | 739,489,441.5 | 452,584,567.2 |
| 固定资产 | 9,391,890,889.95 | 9,321,535,207.65 | 8,738,522,191.19 | 8,714,971,967.4 |
| 在建工程 | 1,205,376,366.04 | 1,267,849,250.12 | 1,753,207,126.83 | 1,776,575,312.69 |
| 使用权资产 | 93,243,404.78 | 99,329,350.88 | 53,806,104.64 | 57,161,554.28 |
| 无形资产 | 1,987,801,303.92 | 1,959,075,008.58 | 2,026,635,361.04 | 2,043,337,696.33 |
| 开发支出 | 673,192,913.53 | 659,243,958.76 | 648,394,403.26 | 641,388,152.85 |
| 商誉 | 729,124,526.53 | 729,148,709.1 | 948,043,223.17 | 948,326,301.45 |
| 长期待摊费用 | 24,799,693.01 | 26,165,509.35 | 30,535,875.82 | 32,024,692.1 |
| 递延所得税资产 | 92,753,836.85 | 92,762,671.4 | 79,985,277.87 | 89,028,651.53 |
| 其他非流动资产 | 415,554,871.79 | 342,024,227.43 | 351,010,177.77 | 252,521,196.25 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 16,754,349,681.82 | 16,649,949,124.87 | 16,858,815,919.39 | 16,509,346,129.14 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 37,166,546,046.65 | 36,508,323,981.75 | 37,345,934,482.88 | 36,580,816,669.84 |
| 流动负债: | | | | |
| 短期借款 | 7,956,629,009.12 | 7,149,572,213.4 | 7,059,777,209.33 | 7,057,714,715.58 |
| 应付票据及应付账款 | 3,047,336,462.67 | 3,083,933,446.29 | 3,103,074,218.41 | 3,037,093,834.23 |
| 其中：应付票据 | 261,216,385.46 | 282,134,915.48 | 256,760,444.65 | 233,598,081.67 |
| 应付账款 | 2,786,120,077.21 | 2,801,798,530.81 | 2,846,313,773.76 | 2,803,495,752.56 |
| 预收款项 | 700,150.14 | 700,150.14 | 5,800,150.14 | 700,150.14 |
| 合同负债 | 325,719,780.05 | 341,605,133.34 | 379,996,004.82 | 396,130,935.91 |
| 应付职工薪酬 | 152,743,862.69 | 344,148,319.33 | 286,776,511.45 | 321,514,106.34 |
| 应交税费 | 318,883,388.39 | 335,919,224.49 | 388,064,899.86 | 357,436,316.68 |
| 其他应付款合计 | 1,136,072,426.64 | 1,183,146,150.39 | 1,439,213,095.49 | 1,379,797,277.71 |
| 应付股利 | 241,938,171.11 | 241,938,171.11 | 435,555,937.03 | 190,717,272.28 |
| 一年内到期的非流动负债 | 686,073,442.15 | 860,609,278.24 | 1,022,299,809.17 | 798,141,980.95 |
| 其他流动负债 | 39,839,267.96 | 40,342,306.32 | 41,919,014.51 | 40,783,681.1 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 13,663,997,789.81 | 13,339,976,221.94 | 13,726,920,913.18 | 13,389,312,998.64 |
| 非流动负债: | | | | |
| 长期借款 | 890,053,551.24 | 1,191,687,462.38 | 1,386,573,336.6 | 1,711,468,623.83 |
| 租赁负债 | 67,058,537.43 | 72,533,309.36 | 34,800,370.82 | 37,264,607.67 |
| 长期应付款 | 16,000,000 | 16,000,000 | 57,075,436.72 | 57,075,436.72 |
| 递延收益 | 793,474,057.57 | 790,525,089.52 | 736,413,207.67 | 711,735,983.35 |
| 递延所得税负债 | 399,497,729.43 | 404,542,912.05 | 384,138,898.46 | 385,706,985.87 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 2,166,083,875.67 | 2,475,288,773.31 | 2,599,001,250.27 | 2,903,251,637.44 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 15,830,081,665.48 | 15,815,264,995.25 | 16,325,922,163.45 | 16,292,564,636.08 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,632,225,965 | 1,632,225,965 | 1,632,257,765 | 1,632,361,067 |
| 资本公积 | 5,684,298,344.61 | 5,684,298,344.61 | 5,686,155,520.48 | 5,685,364,310.13 |
| 减:库存股 | - | - | 408,312 | 87,562,911.77 |
| 其他综合收益 | 96,841,642.55 | 126,430,409.81 | 109,478,247.92 | -146,967,646.05 |
| 盈余公积 | 592,578,811.67 | 592,578,811.67 | 489,525,634.92 | 489,525,634.92 |
| 未分配利润 | 10,128,630,807.38 | 9,588,285,347.99 | 9,951,491,183.5 | 9,717,605,105.78 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 18,134,575,571.21 | 17,623,818,879.08 | 17,868,500,039.82 | 17,290,325,560.01 |
| 少数股东权益 | 3,201,888,809.96 | 3,069,240,107.42 | 3,151,512,279.61 | 2,997,926,473.75 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 21,336,464,381.17 | 20,693,058,986.5 | 21,020,012,319.43 | 20,288,252,033.76 |
| 负债和股东权益合计 | 37,166,546,046.65 | 36,508,323,981.75 | 37,345,934,482.88 | 36,580,816,669.84 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-30 | 2024-07-27 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |